A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of RVX000222 Capsule Formulation in Combination With Either Atorvastatin or Rosuvastatin in Patients With Dyslipidemia

Trial Profile

A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of RVX000222 Capsule Formulation in Combination With Either Atorvastatin or Rosuvastatin in Patients With Dyslipidemia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 May 2015

At a glance

  • Drugs Apabetalone (Primary) ; Atorvastatin; Rosuvastatin
  • Indications Coronary artery disease; Dyslipidaemias
  • Focus Pharmacokinetics
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 28 Jun 2013 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top